Drug Trial Radar · NCT01545076
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Last checked: Nov 19, 2026Latest source record: Jul 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
208
Actual
Start
Mar 2012
Primary completion
Sep 2016
Study completion Sep 2016
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- Collaborators
- ICON Clinical Research
- First posted
- Mar 6, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group 3-arm study to investigate 2 different doses of subcutaneous (SC) IgPro20 compared with placebo for maintenance treatment of patients with CIDP. Patients who received at lease 1 dose of intravenous immunoglobulin (IVIG) within 8 weeks before screening will be assessed during 4 separate study periods. Patients first undergo a Screening Period, followed by an IgG Dependency Test Period of up to 12 weeks to test for ongoing need of IgG. Those patients experiencing CIDP relapse during this test period will be administered a standardized IVIG regimen during an IVIG Re-stabilization Period. Patients with improved and maintained adjusted inflammatory neuropathy cause and treatment scale (INCAT) in the IVIG Re-stabilization Period will continue to the SC Treatment Period of the study. Patients entering the 24 week SC Treatment Period will be randomized to receive weekly infusions of 1 of 2 IgPro20 doses (0.2 or 0.4 g/kg body weight) or placebo. The overall study duration is up to 52 weeks. Clinical outcomes will be assessed by the Inflammatory Neuropathy Cause and Treatment (INCAT) score, maximum grip strength, the Medical Research Council (MRC) sum score, the Rasch-built Overall Disability Scale (R-ODS), and electrophysiological evaluations.
Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Polyradiculoneuropathy
Interventions
IgPro20 (low dose)Biological
20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization: 0.2 g/kg body weight (low dose arm)
PlaceboBiological
2% human albumin administered by weekly SC infusions during the SC treatment period of the study.
IgPro10Biological
10% Immunoglobulin G (IgG) liquid formulation of human normal immunoglobulin (Privigen®) administered intravenously during Restabilization Period of the study and/or as Rescue Therapy during SC Treatment Period for subjects with a CIDP relapse.
IgPro20 (high dose)Biological
20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization: 0.4 g/kg body weight (high dose arm)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage (%) of Subjects With CIDP Relapse or Are Withdrawn for Any Other Reason During the Subcutaneous (SC) Treatment PeriodTime frame: Up to 25 weeks
Locations
91 sites in 16 countries. Site status is shown where the registry gives one.
Site reference 8400181
Birmingham, Alabama
Site reference 8400173
Phoenix, Arizona
Site reference 8400172
Phoenix, Arizona
Site reference 8400167
Los Angeles, California
Site reference 8400077
Centennial, Colorado
Site Reference 8400352
Washington D.C., District of Columbia
Site reference 8400214
Miami, Florida
Site reference 8400162
Chicago, Illinois
Site Reference 8400247
Chicago, Illinois
Site Reference 8400215
Indianapolis, Indiana
Site reference 8400166
Kansas City, Kansas
Site Reference 8400347
New Brunswick, New Jersey
Site reference 8400169
New York, New York
Site reference 8400179
New York, New York
Site reference 8400182
Charlotte, North Carolina
Site Reference 8400346
Durham, North Carolina
Site reference 8400178
Columbus, Ohio
Site reference 8400217
Oklahoma City, Oklahoma
Site Reference 8400177
Nashville, Tennessee
Site reference 8400164
Houston, Texas
Site Reference 8400268
Charlottesville, Virginia
Site Reference 8400340
Seattle, Washington
Site reference 0360008
Southport, Australia
Site Reference 0360017
Herston, Queensland, Australia
Site reference 0360011
Fitzroy, Victoria, Australia
Site reference 0560003
Leuven, Belgium
Site reference 1240006
Edmonton, Canada
Site reference 1240007
Québec, Canada
Site reference 1240009
Toronto, Canada
Site Reference 1240048
Vancouver, British Columbia, Canada
Site Reference 1240051
Montreal, Quebec, Canada
Site reference 2030002
Hradec Králové, Czechia
Site reference 2030009
Hradec Králové, Czechia
Site reference 2030003
Prague, Czechia
Site Reference 2330002
Tallinn, Estonia
Site Reference 2330003
Tallinn, Estonia
Site reference 2460002
Helsinki, Finland
Site reference 2500024
Clermont-Ferrand, France
Site reference 2500013
Marseille, France
Site reference 2500022
Nice, France
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.